Expert Interview
Delving into RAPT Therapeutics phase 2 trial data of RPT904 (JYB1904) in chronic spontaneous urticaria
Ticker(s): RAPTInstitution: Institute For Asthma & Allergy
- Director of the Center for Urticaria and Angioedema at the Institute For Asthma & Allergy.
- Manages 200 pateints for peanut allergies
- Also maintains a part-time faculty position at the Johns Hopkins.
What are your thoughts on the phase 2 trial data for RPT904 (JYB1904)?
Added By: emily_adminWhat impact do you think RPT904 will have on the treatment space for patients with CSU?
Added By: emily_adminWhat are your thoughts on the mechanism of action of RPT904?
Added By: emily_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
